Molbio Diagnostics

1.1 Identity and operating model

Molbio Diagnostics Limited was incorporated in 2000 and is headquartered in Goa. The business develops and commercializes point-of-care molecular diagnostics, with Truenat as its portable PCR platform and disease-specific assays or test kits as the associated consumable. Company and broker descriptions place the system in resource-limited and near-patient settings and cover infectious and non-communicable disease testing. This device-plus- consumables description is a product model, not a disclosed recurring-revenue percentage. Geojit's IPO note reports FY26 consolidated Sales separately from The Economic Times' FY25 revenue-from-operations figure; the different metric labels and fiscal periods are retained rather than normalized.[CO001, CO009, CO010, CO011]

1.2 Leadership and governance

The latest assigned leadership disclosures identify Sriram Natarajan as executive director and CEO, Dr. Chandrasekhar Bhaskaran Nair as executive director and CTO, and Sangeetha Sriram as executive director and director of operations. The RHP and Geojit research note also describe three independent directors. This documents named functional coverage and formal board independence; it does not establish succession depth, retention arrangements, or the degree to which product development and commercial execution depend on particular individuals. Those matters remain unquantified in the retained evidence.[CO013, CO014]

1.3 Capital and stakeholders

The August 2026 IPO comprised a ₹200 crore fresh issue and a ₹739.70 crore offer for sale, for a reported total issue of about ₹939.70 crore. The fresh issue was designated for an R&D facility and Centre of Excellence and for manufacturing equipment; the OFS component represented sales by existing holders, not proceeds available to Molbio. A May 2024 Moneycontrol report separately described an approximately ₹680 crore 2022 financing and an anonymously sourced proposed valuation target for a then-planned IPO. That historical target is not the IPO's realized valuation or a current public market value, and the reported financing does not establish cumulative funds raised or cash on hand.[CO012, CO015]

1.4 Milestones, concentration and evidence limits

The dated record traces a company-reported Molbio–Bigtec technology combination, WHO-recognized Truenat assays, international public-health collaboration, portfolio acquisitions and the 2026 listing. Company heritage material is the source for several historical milestones; the Global Fund announcement and Business Today coverage provide external corroboration for selected events. Geojit's August 2026 IPO note flags that government and aid agency contracts contributed about 85% of FY26 revenue and TB diagnostic kits about 70% of FY26 revenue. These are source-reported concentration measures, not independently reconciled customer-level data. The assigned sources do not provide a dated current customer count or post-listing market capitalization.[CO002, CO003, CO004, CO005, CO006, CO007, CO008, CO016]

2.1 Market boundary and sizing discipline

The closest market proxy in the assigned source set is global point-of-care molecular diagnostics: rapid molecular tests performed near the patient, rather than the full diagnostics industry. Grand View Research estimates this category at USD 8.7 billion in 2025 and forecasts USD 14.5 billion by 2033, but the estimate spans multiple diseases, technologies, care settings, and regions (CM001). Its infectious-disease application share of 47% is a broad subset, not a TB-specific opportunity (CM002). India broker estimates cover the much wider diagnostics market, including radiology, and cannot be substituted for an India molecular-testing SAM (CM003). Radiology, digital pathology, and breast-health products are relevant Molbio adjacencies but sit outside this molecular-market proxy (CM007, CM010).[CM001, CM002, CM003, CM007, CM010]

2.2 Multiple sizing lenses, not a company TAM

The global category estimate provides a directional top-down lens, not a valuation-ready Molbio TAM. Grand View reports a 2025 base, a 2026 estimate, and a 2033 forecast; its published methodology describes a supply- and demand-side triangulation, but the result remains a third-party market estimate rather than company revenue guidance (CM001). Its 47% infectious-disease share implies approximately USD 4.1 billion of 2025 global category revenue when applied to the USD 8.7 billion base; this is a rounded calculation across all infectious diseases, not TB market spend (CM002). Two Indian broker notes put the broader FY26 diagnostics market near ₹1.35 trillion and describe IVD as 56.1% of it, while explicitly including in-vivo radiology in the broad category (CM003). The WHO page for its 2024 TB report warns that those burden estimates are outdated and superseded annually, so it cannot close the current India demand gap (CM004). The sizing layers below therefore leave TB-, India-, and company-specific amounts unvalued rather than fabricating a SAM or SOM.[CM001, CM002, CM003, CM004, CM015]

2.3 Buyers, users, and the adoption path

GEPL Capital describes the customer universe as government health programs, hospitals, diagnostic laboratories, and international healthcare organizations (CM011). In public and aid-funded settings, the budget owner is likely to be a procurement agency or program sponsor, while clinicians and laboratory staff use the test; the assigned sources do not disclose buyer-level budget authority or contract conversion. Molbio's device-plus-proprietary-kit model makes installation only the first adoption step: recurring test consumption and reliable service are needed for an installed instrument to produce sustained revenue. India Health Fund's partner page describes the Truelab platform for resource-limited settings and asserts lower per-test cost than other RT-PCR tests, but supplies no current price or comparable cost study (CM012). The company's 12,500-plus device base and 43-assay menu are evidence of reach, not proof of active utilization or demand by assay (CM006, CM007).[CM006, CM007, CM011, CM012]

2.4 Growth drivers, constraints, and unresolved demand

The category tailwinds are faster near-patient decisions and decentralized testing, while the company-specific route to growth depends on kit consumption, broader assays, and utilization of existing capacity. Molbio and its broker both report FY26 kit and device capacity utilization of 58% and 42%, respectively, leaving headroom but not demonstrating realized sell-through (CM009). The company also describes an additional assay pipeline, which remains planned rather than commercialized demand (CM010). Grand View identifies instrument, implementation, recurring consumable, quality-control, and training costs as adoption constraints, especially for lower-budget providers (CM013). Q1 FY27 results included export orders deferred from the prior quarter, and management cautions that quarterly revenue is non-linear; one strong quarter is therefore not a stable market run rate (CM014). Updated India TB test volumes, test-level pricing, procurement awards, and active-instrument utilization are needed before an investor can size an India/TB SAM or company SOM (CM015).[CM009, CM010, CM013, CM014, CM015]

2.5 Exhibits

3.1 Competitive set and buyer alternatives

WHO's current TB testing framework places Molbio's Truenat MTB Plus with MTB-RIF Dx and Cepheid's Xpert MTB/RIF Ultra in the low-complexity automated nucleic-acid amplification test class for initial TB detection and rifampicin resistance. That makes Xpert the clearest documented direct alternative in the assigned evidence, rather than a broad molecular-diagnostics company comparison. Smear microscopy and culture remain relevant status-quo comparators in the clinical studies, while centralized laboratory workflows are substitutes for decentralized deployment. Unitaid describes work to accelerate new point-of-care molecular systems and assays, but the retained source does not name specific competing entrants. No assigned source establishes internal-build prevalence, market shares, or competitor scale.[CP001, CP010, CP011]

3.2 Capability and clinical-evidence comparison

Independent evaluations provide useful but bounded head-to-head evidence. In Cameroon, Truenat MTB Plus sensitivity against culture was 91% (95% CI, 86–94%) versus 90% for Xpert, while specificity was 96% versus 99%; the study included 945 outpatients and 251 culture-positive participants. A separate 250-participant Uganda study reported 80.5% sensitivity and 98.1% specificity against Xpert Ultra, using its stated denominators and confidence intervals. These are not pooled estimates and should not be generalized across settings. The Uganda study also reported error/invalid tests and uninterpretable rifampicin-resistance results. A separate four-country Truenat MTB Ultima/COVID-19 paper is a study protocol with planned enrollment, not published comparative performance results.[CP002, CP003, CP004, CP005, CP010, CP011]

3.3 Pricing, distribution, and access dynamics

The reviewed sources describe a product workflow and access ecosystem, but do not establish an apples-to-apples commercial comparison. Molbio's own product page describes chip-based real-time PCR and a one-hour sample-to- result claim; a PharmaBiz interview relays similar statements from the company's president, so those statements remain company-claimed rather than independent benchmarks. CHAI describes country-level work on diagnostics access, procurement, supply chains, training, and integration with care, while Unitaid describes support for new technology classes and partner manufacturers. These organizations shape adoption conditions; the sources do not show that either is a Molbio reseller or quantify Molbio- specific placement terms. Public evidence here does not resolve instrument price, assay price, discounts, or contract structure.[CP006, CP007, CP008, CP009, CP012]

3.4 Durability, switching, and unresolved risks

Truenat's differentiation is plausibly tied to decentralized molecular testing, but the evidence does not establish a durable cost or distribution moat. WHO's framework notes that low-complexity automated NAATs still require laboratory networks and trained personnel, so instrument portability alone does not demonstrate reliable service at the point of care. The Uganda evaluation's reported errors and uninterpretable rifampicin-resistance results are a concrete execution caveat, not proof of a persistent product defect. The assigned evidence does not quantify uptime, service response, multi-homing, switching costs, internal-build rates, or realized pricing. These gaps prevent a defensible ranking of lifetime economics or moat durability against Xpert and newer entrants.[CP001, CP004, CP009, CP012, CP013]

4.1 Revenue model, mix, and quality

Molbio's Truenat model pairs device sales with disease-specific test kits that generate repeat purchases; this supports recurring consumables revenue, not a disclosed subscription or ARR measure (CI001). For FY26, Motilal Oswal's summary puts Truenat at about 90% of revenue, with test kits at 72% and devices at 14% of consolidated revenue; it reports kit revenue of Rs 10.3 billion and device revenue of Rs 2.0 billion (CI003, CI004). Anand Rathi reports consolidated revenue from operations of Rs 8,366 million in FY24, Rs 10,204 million in FY25, and Rs 14,457 million in FY26 (CI002). These measures evidence scale and a consumables-led mix, but not ARR, paid-test utilization, customer retention, or product gross profit. FY26 concentration is material: government and aid agencies contributed 84.6% of revenue, the top ten customers 83.3%, and TB test kits 70.2% (CI007-CI009). These overlapping payer, customer, and disease denominators must not be added together.[CI001, CI002, CI003, CI004, CI007, CI008, CI009, CI014]

4.2 Margins, pricing, and unit-economics gaps

Consolidated EBITDA margin fell from 28.0% in FY24 to 25.7% in FY25 and 22.2% in FY26, even as revenue grew; Motilal Oswal attributes FY26 pressure to higher employee and other expenses, R&D, overseas-market development, and sales costs (CI005). The same broker describes FY24-FY26 operating cash flow as volatile because of working-capital intensity, receivables, and inventory; Anand Rathi also flags past negative operating cash flows at the company and certain subsidiaries without giving their period or amount (CI006). Neither statement establishes FY26 cash burn. The only explicit per-test price in this source set is a Stop TB Partnership quote in a 2023 Global Fund release: below US$8 per test under a specific collaboration, alongside a service-level agreement (CI013). It is not a current list price, realized ASP, or gross-margin measure. WHO's technical review likewise does not establish commercial uptake (CI016).[CI005, CI006, CI013, CI015, CI016]

4.3 Capital adequacy and underwriting verdict

Anand Rathi's August 2026 IPO note reports an Rs 9,400 million offer, split between Rs 2,000 million of fresh issue and Rs 7,400 million of offer for sale; Business Today later reported an approximately Rs 940 crore IPO raise and the Rs 807 issue price (CI010, CI011). The gross issue amount therefore is not the amount of new company capital: the OFS portion represents selling shareholders. The fresh-issue objects included an R&D facility and Center of Excellence, plant and equipment, and general corporate purposes; a CEO interview also described R&D-facility and manufacturing-automation plans (CI012). Neither the offer documents in this pool nor the post-listing interview establishes current cash on hand, debt maturities, monthly burn, net proceeds after costs, or runway. The underwriting case has demonstrated revenue scale, but margin compression, concentrated demand, working-capital volatility, and missing liquidity data make returns and capital sufficiency hard to underwrite. Request current interim cash-flow and balance-sheet data plus assay-level margins, utilization, pricing, and receivables detail.[CI010, CI011, CI012]

5.1 Product and customer workflow

Molbio positions Truenat as portable, battery-operated molecular testing for point-of-care and field use. Its product material describes Trueprep AUTO V2 for nucleic-acid extraction followed by Truelab micro-PCR amplification with disease-specific chips; Geojit's 2026 research note describes the same instrument-and-consumable configuration (CE001, CE002). The company gives separate 20-minute extraction and 35-minute process statements, but the latter is not clearly labelled as an end-to-end time. Geojit reports 43 assays across 30 diseases, an analyst-reported menu count rather than independent evidence for each assay (CE004). TB is the most concretely documented workflow in this source set; adjacent radiology and digital-pathology lines have less product-level detail (CE012, CE015).[CE001, CE002, CE004, CE015]

5.2 TB use case and comparative evidence

WHO's 2020 rapid communication noted new evidence on Truenat MTB and MTB Plus within its TB diagnostic review; the Global Fund later reported WHO endorsement of named Truenat TB assays and announced a partner program covering reduced prices and service commitments (CE005, CE012). A peer-reviewed economic analysis used data from a multicentre randomized trial comparing decentralized Truenat MTB Plus and MTB-RIF Dx with hub-and-spoke Xpert MTB/RIF Ultra in Mozambique and Tanzania (CE006). Its facility-based cost per participant initiating treatment differed by country and by whether initiation was measured within seven or sixty days; the published intervals overlap in some comparisons, and decentralized testing was not uniformly less costly at the later horizon (CE007, CE008). Testing volume was the strongest reported driver of cost-effectiveness, so these findings are setting-specific rather than a universal product or competitor benchmark (CE009).[CE005, CE006, CE007, CE008, CE009, CE012]

5.3 Deployment model and operating dependencies

The platform couples instruments to repeat-use assay consumables, while partner and analyst sources describe deployment through public-health programs, laboratories, and hospitals. The Global Fund's 2023 release set out reduced-price TB tests and a service-level agreement with defined indicators; that documents a commercial support commitment, not achieved response times or uptime (CE003, CE005). Public reports also provide capacity and deployment snapshots: the DRHP coverage cited by The Economic Times gives FY25 installed capacity, while Geojit's August 2026 note reports FY26 capacity and devices sold across more than 90 countries (CE010, CE011). These are installed-capacity and reported installed-base measures, not factory output, utilization, or active customers. Geojit separately flags government/aid-agency and TB-kit concentration in FY26 revenue, which makes procurement and disease mix material operating dependencies (CE013, CE014).[CE003, CE005, CE010, CE011, CE013, CE014, CE016]

5.4 Differentiation, roadmap, and trust gaps

Truenat's differentiating proposition is an instrument-plus-assay workflow designed for decentralized PCR, not demonstrated superiority across every disease or care setting (CE001, CE003). Business Today TV's August 2026 interview summary identifies expansion into new disease areas, international markets, digital pathology, and veterinary diagnostics as topics discussed with Molbio's CEO; this is evidence of stated direction, not proof of launch, integration, or commercial maturity (CE015). Geojit flags slower adoption, tender cycles, regulatory delays, patent challenges, and reduced global TB funding among risks (CE016). The assigned evidence does not quantify assay-specific sensitivity or failure rates, device-level service outcomes, or cybersecurity and privacy controls. Those omissions do not establish that controls or incidents are absent; they leave field readiness and connected-result handling unverified and require direct quality, service, and security diligence.[CE001, CE003, CE015, CE016]

6.1 Buyer mix is disclosed by category, not by account

GEPL Capital's August 2026 IPO note groups FY26 revenue into Indian central government, Indian state governments, international aid agencies, and non-government agencies. It reports ₹791 crore (56.54%) from the central government category, ₹326 crore (23.30%) from state governments, ₹66 crore (4.72%) from international aid agencies, and ₹216 crore (15.44%) from non-government agencies. These categories indicate that public budgets and aid-funded programs are major payer channels, but they do not identify ministries, tenders, countries, or individual customers. NDTV Profit estimates that only about 1,400 of 17,000 private healthcare facilities have molecular diagnostic capability; that is a market estimate, not a count of Molbio customers. The source's FY26 category table totals ₹1,399 crore, while its financial table reports ₹1,446 crore of revenue, so the percentage mix should not be reconciled to another denominator.[CU005, CU008, CU009, CU010]

6.2 Deployment and kit volume show activity, not site-level utilization

NDTV Profit reports more than 12,500 Truenat devices across over 90 countries and describes an Indian public-sector footprint of about 8,000–9,000 public health centres. DSIJ's October 2026 summary of Motilal Oswal research also gives 12,500-plus devices and 8,000–9,000 diagnostic centres, without defining the centre population in the same way. An undated OpenDx profile separately lists 8,293-plus NAAT systems in India and 85-plus countries; these differently worded counts are not interchangeable. NDTV reports test-kit volumes rising from 8.8 million units in FY24 to 17.6 million in FY26 (41% CAGR), while GEPL rounds those fiscal-year totals to 9 million and 18 million. It also reports more than 40 million tests worldwide without specifying the period. Sales, devices, centres, and cumulative tests evidence activity, not active use or reorder frequency at a particular customer.[CU001, CU002, CU003, CU004]

6.3 Program announcements prove routes to market, not customer outcomes

The strongest named customer-side evidence in the assigned sources is institutional and programmatic. The Global Fund's March 2023 announcement describes lower prices for Truenat TB tests and a global service and maintenance agreement with defined performance indicators; it says new deals would be signed, not that all orders had shipped. A company announcement reproduced by IndiaMedToday reports a completed domestic rollout under India's National Tuberculosis Elimination Program and an iNTP rollout across nine countries, with installations described as complete in seven and underway in Bangladesh and Vietnam. These records identify buyers, funders, and implementation pathways, but disclose no country-level order values, active-site counts, or patient outcomes. WHO's rapid communication provides clinical-evidence context, not proof of customer utilization.[CU010, CU011, CU012, CU013, CU016]

6.4 Recurring kit sales coexist with buyer and disease concentration

Truenat combines device placements with proprietary single-use kits, so ongoing testing can generate repeat consumable purchases. Aggregate kit growth does not establish customer retention: the assigned sources do not report net or gross revenue retention, churn, renewal cohorts, contract duration, or reorder frequency by site. Concentration is clearer at the payer-category and disease levels. GEPL's customer table shows sizable central- and state-government shares, while NDTV Profit and analyst notes flag public procurement and tuberculosis dependence. Their TB metrics use different bases—total revenue, consumables revenue, and test-kit volume— and should not be blended. A May 2024 Moneycontrol article reported plans to strengthen global presence and launch products; this is historical intent, not evidence of achieved expansion. Account-level concentration, active utilization, and renewal behavior remain material diligence gaps.[CU005, CU006, CU007, CU014, CU015, CU016]

7.1 Legal and regulatory exposure

The August 3, 2026 red herring prospectus is the strongest current source for legal and regulatory exposure. It reports pending proceedings across the company, subsidiaries, promoters, and directors, including 11 tax proceedings against the company with an aggregate amount of ₹507.81 million; the amount is a claim disclosed in the filing, not an adjudicated loss. Separately, the filing describes a July 2026 information notice to Prognosys concerning an investigation involving a former customer, and says Prognosys supplied the requested documents. It also identifies permit, inspection, and changing-rule risks, plus earlier statutory-compliance failures for which stated penalties were paid. The probability, resolution timetable, and any continuing control remediation are not quantified, so diligence should obtain counsel's matter-by-matter status and the current approval register. (CR004, CR005, CR006)[CR004, CR005, CR006]

7.2 Product, quality, and operating continuity

The prospectus identifies product accuracy, defects, warranty obligations, facility disruption, demand forecasting, and privacy or cyber threats as potential business risks. It reports ₹232.17 million of warranty provision at March 31, 2026 and says it has not had a product-liability claim with an adverse business impact in the prior three fiscal years; that statement is not evidence that no complaints or quality incidents occurred. It also describes prior inventory-obsolescence provisions and a two-year shelf life for Truenat kits. NatCap independently highlights assay breadth, quality, and distribution as execution challenges, but supplies no incident rate or control assessment. The investment case therefore depends on audited quality metrics, field failure and complaint data, CAPA closure, and service performance that are not public in this source set. (CR003, CR007, CR010, CR012, CR016)[CR003, CR007, CR010, CR012, CR016]

7.3 Customer, supplier, and partner dependencies

FY26 finished-goods revenue concentration is unusually consequential: Indian central and state governments plus international aid agencies represented 84.56%, the top ten customers 83.26%, and TB test kits 70.20% of the same stated denominator. ICICI Direct separately notes that none of the top ten customers was under a firm-commitment contract. Supplier exposure is also concentrated: the prospectus says the top ten suppliers represented 58.52% of raw-material purchases and identifies a substrate sole-source; ICICI Direct reports 42.01% of FY26 raw materials were imported. A Global Fund/USAID/Stop TB collaboration documents reduced test prices and defined service-level KPIs, but not the economics or service outcomes. These disclosures support concentration and dependency concerns, not a forecast that any contract or supplier will fail. (CR001, CR002, CR008, CR009, CR011, CR015)[CR001, CR002, CR008, CR009, CR011, CR015]

7.4 Financial resilience and monitoring priorities

The prospectus reports FY26 working capital of ₹8,274.83 million and working-capital days of 166, while consolidated borrowings were ₹4,225.01 million as of May 31, 2026; ₹392.43 million of unsecured loans were repayable on demand. These are balance-sheet and financing exposures, not a cash-burn measure. The filing also warns that the proposed R&D and Center of Excellence facility would not add manufacturing capacity or immediate attributable cash flows, making completion, regulatory clearance, assay launch, and commercial uptake relevant milestones. Track tender renewals and top-customer shares, assay approval and launch timing, warranty and CAPA trends, supplier alternatives, receivable aging, debt covenants, and capex delivery. Public disclosures do not establish customer-level concentration, uptime, incident frequency, or mitigation effectiveness; those remain diligence asks. (CR003, CR013, CR014)[CR003, CR013, CR014]

7.5 Exhibits

8.1 Investment view: quality is not a price

The investment case rests on Molbio's Truenat platform and repeat disease-specific test-kit sales. DSIJ's summary of Motilal Oswal attributes 72% of consolidated FY26 revenue to test kits and 14% to devices, while saying Truenat contributed about 90%; that supports a consumables thesis, not proof of device utilization, reorder behavior or assay-level margins. Geojit reports FY26 revenue of INR 1,445.7 crore, up 41.7% year over year, but the same source set also reports material tuberculosis and government-program concentration. Molbio's September 2022 $1.6 billion financing valuation and Moneycontrol's 2024 reported IPO target are historical reference points, not current fair value. The IPO and public-market snapshots now provide observed prices and multiples, but they do not reconcile to audited current earnings, diluted shares, net debt or a defensible return range. Track is therefore more supportable than Buy until those inputs are checked.[CV001, CV002, CV009, CV010, CV016]

8.2 Public-market entry and valuation evidence

Geojit and GEPL Capital's August 2026 IPO notes report a price band of INR 768–807 and roughly INR 9,300 crore market capitalization at the upper band. Geojit's upper-price issue table lists about INR 940 crore of total offer, including INR 200.2 crore of fresh issue and INR 739.7 crore of OFS; its allocation table reports INR 939.7 crore total against the issue-size table's INR 939.9 crore, a small internal discrepancy. The total offer size is not cash available to Molbio because OFS proceeds go to selling shareholders. The Economic Times' 2025 DRHP coverage described an earlier proposed INR 200 crore fresh issue and OFS of up to 1.25 crore shares, so that proposal should not be confused with the final 2026 issue. Business Today reports a debut at INR 980, over 21% above the INR 807 issue price. Multiples.vc's October 25, 2026 snapshot lists USD 1.5 billion market capitalization and enterprise value, 10.2x EV/Revenue and 45.4x EV/EBITDA; its revenue period and valuation bridge are not clear enough for independent recalculation. DSIJ's summary of Motilal Oswal's INR 1,800 target is an analyst view, not a verified fair-value conclusion.[CV003, CV004, CV005, CV006, CV007, CV008, CV013]

8.3 Scenario discipline and downside

The bull case is that kit consumption, new assays and international penetration deliver the FY26–FY29E revenue CAGR and margin expansion in Motilal Oswal's forecast as summarized by DSIJ. Those are analyst estimates, not company guidance or probability-weighted outcomes. The base case is continued growth but no fresh entry until the October market-data snapshot is reconciled to the live quote, diluted share count, net debt and FY26/interim earnings. The bear case is multiple compression or slower growth if tuberculosis testing and public procurement remain concentrated, while margin pressure offsets revenue growth. DSIJ reports TB at 96% of FY26 test-kit volume and 74% of consumables revenue; Geojit reports government and aid agencies at about 85% of FY26 revenue. Neoma's August pre-IPO note separately warns that procurement dependence can expose revenue to funding and policy decisions. The broker's comparison set is a valuation reference only, not an independent fair-value benchmark. The available evidence does not support numerical scenario ranges or probabilities.[CV008, CV010, CV011, CV012, CV013, CV014, CV015, CV016]

8.4 Exit readiness, diligence and thesis breaks

Molbio's 2026 listing provides public-market access, but investor exit readiness still depends on the live trading price, liquidity, lock-ups, fully diluted ownership and post-IPO selling by shareholders. The available offer notes distinguish fresh issue from OFS but do not establish current free float, preference overhang, lock-up schedules or a same-date equity-to-enterprise-value bridge. Before entry, obtain the latest exchange filings and shareholding pattern, rebuild enterprise value from the current quote and net debt, and reconcile audited and interim financials with broker forecasts. Disease-level sales, customer and tender concentration, device utilization, receivable days, inventory and operating cash flow are needed to distinguish accounting profit from cash conversion. Reassess the thesis if revenue fails to track the published FY26–FY29E broker forecast, TB or public-procurement concentration persists without diversification, or margins and cash conversion weaken. These are diligence and monitoring triggers, not claims that deterioration has occurred.[CV003, CV005, CV006, CV009, CV010, CV011, CV012, CV014, CV016]